-
公开(公告)号:US07915280B2
公开(公告)日:2011-03-29
申请号:US11213712
申请日:2005-08-30
申请人: Dana Victor Ferraris , Jia-He Li , Vincent Kalish , Jie Zhang
发明人: Dana Victor Ferraris , Jia-He Li , Vincent Kalish , Jie Zhang
IPC分类号: A61K31/4375 , A61K31/55 , A61K31/551
CPC分类号: A61K31/55 , A61K31/551 , C07D471/04 , C07D487/06 , C07D495/06
摘要: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
摘要翻译: 本发明涉及化合物,药物组合物和使用所公开的化合物抑制PARP的方法。
-
2.Compounds, methods and pharmaceutical compositions for inhibiting PARP 有权
标题翻译: 用于抑制PARP的化合物,方法和药物组合物公开(公告)号:US07750008B2
公开(公告)日:2010-07-06
申请号:US12540776
申请日:2009-08-13
申请人: Vincent Kalish , Jie Zhang , Weizheng Xu , Jia-He Li , Amy D. Xing , Qun Liu
发明人: Vincent Kalish , Jie Zhang , Weizheng Xu , Jia-He Li , Amy D. Xing , Qun Liu
IPC分类号: C07D487/06 , A61K31/5025
CPC分类号: C07D487/06 , C07D471/06 , C07D491/06 , C07D491/08
摘要: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
摘要翻译: 本发明提供了抑制聚(ADP-核糖)聚合酶(“PARP”),含有这些化合物的组合物和使用这些PARP抑制剂治疗,预防和/或改善本文所述病症的作用的方法的化合物。
-
3.N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors 有权
标题翻译: N-羟基磺酰胺衍生物作为新的生理有用的硝酰基供体公开(公告)号:US20070299107A1
公开(公告)日:2007-12-27
申请号:US11724792
申请日:2007-03-16
申请人: John Toscano , Frederick Brookfield , Andrew Cohen , Stephen Courtney , Lisa Frost , Vincent Kalish
发明人: John Toscano , Frederick Brookfield , Andrew Cohen , Stephen Courtney , Lisa Frost , Vincent Kalish
IPC分类号: A61K31/18 , A61K31/381 , A61K31/47 , A61P9/00 , C07C311/16 , C07D215/36 , C07D333/34
CPC分类号: C07C311/48 , C07C317/14 , C07C323/67 , C07D213/74 , C07D231/18 , C07D261/10 , C07D263/58 , C07D285/125 , C07D295/096 , C07D307/82 , C07D309/12 , C07D317/14 , C07D333/34 , C07D333/62
摘要: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.
摘要翻译: 本发明涉及在生理条件下给予硝酰基(HNO)的N-羟基磺酰胺衍生物,并且可用于治疗和/或预防对硝酰病治疗有反应的疾病或病症的发作和/或发展,包括心力衰竭和缺血/再灌注 伤害。 新的N-羟基磺酰胺衍生物在生理条件下以受控的速率释放NHO,并且通过改变N-羟基磺酰胺衍生物上官能团的性质和位置来调节HNO释放速率。
-
公开(公告)号:US20060003987A1
公开(公告)日:2006-01-05
申请号:US11213712
申请日:2005-08-30
申请人: Dana Ferraris , Jia-He Li , Vincent Kalish , Jie Zhang
发明人: Dana Ferraris , Jia-He Li , Vincent Kalish , Jie Zhang
IPC分类号: A61K31/55 , A61K31/551 , C07D498/02
CPC分类号: A61K31/55 , A61K31/551 , C07D471/04 , C07D487/06 , C07D495/06
摘要: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
摘要翻译: 本发明涉及化合物,药物组合物和使用所公开的化合物抑制PARP的方法。
-
公开(公告)号:US20050148575A1
公开(公告)日:2005-07-07
申请号:US11066478
申请日:2005-02-28
申请人: Dana Ferraris , Jia-He Li , Vincent Kalish , Jie Zhang
发明人: Dana Ferraris , Jia-He Li , Vincent Kalish , Jie Zhang
IPC分类号: C07D487/04 , A61K31/4745 , A61K31/496 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K31/5517 , A61P1/00 , A61P1/04 , A61P3/00 , A61P3/10 , A61P7/00 , A61P9/00 , A61P9/08 , A61P9/10 , A61P13/12 , A61P19/02 , A61P19/06 , A61P19/10 , A61P21/00 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/16 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/04 , A61P31/18 , A61P35/00 , A61P37/02 , A61P43/00 , C07D471/04 , C07D487/06 , C07D495/04 , C07D495/06 , C07D519/00 , C07D487/02 , C07D498/02
CPC分类号: A61K31/55 , A61K31/551 , C07D471/04 , C07D487/06 , C07D495/06
摘要: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
摘要翻译: 本发明涉及化合物,药物组合物和使用所公开的化合物抑制PARP的方法。
-
公开(公告)号:US20050070719A1
公开(公告)日:2005-03-31
申请号:US10499675
申请日:2002-12-26
申请人: Sergei Belyakov , Gregory Hamilton , David Hurst , Vincent Kalish , Weixing Li , Eric Wang , Douglas Wilkinson , Yong-Qian Wu , Weizheng Xu
发明人: Sergei Belyakov , Gregory Hamilton , David Hurst , Vincent Kalish , Weixing Li , Eric Wang , Douglas Wilkinson , Yong-Qian Wu , Weizheng Xu
IPC分类号: C07D295/18 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/404 , A61K31/426 , A61K31/427 , A61K31/4453 , A61K31/472 , A61K31/4725 , A61K31/5375 , A61K38/00 , A61K45/00 , A61P1/14 , A61P3/04 , A61P3/06 , A61P3/08 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/10 , A61P15/00 , A61P15/16 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/18 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/06 , A61P39/02 , A61P41/00 , A61P43/00 , C07D205/04 , C07D207/04 , C07D207/16 , C07D207/20 , C07D207/22 , C07D209/18 , C07D209/42 , C07D209/46 , C07D209/48 , C07D217/14 , C07D217/16 , C07D217/22 , C07D217/26 , C07D233/60 , C07D263/06 , C07D277/04 , C07D277/06 , C07D295/125 , C07D295/185 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D409/06 , C07D417/06 , C07K5/078 , C07K5/097
CPC分类号: C07D209/48 , A61K38/00 , C04B35/632 , C07D205/04 , C07D207/04 , C07D207/16 , C07D207/20 , C07D207/22 , C07D209/42 , C07D209/46 , C07D217/14 , C07D217/16 , C07D217/26 , C07D263/06 , C07D277/04 , C07D277/06 , C07D295/125 , C07D295/185 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D409/06 , C07D417/06 , C07K5/06156 , C07K5/0821
摘要: Novel inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, and of such other enumerated conditions as can be treated with inhibitors of DPP IV.
摘要翻译: 提供了二肽基肽酶IV(DPP IV)的新型抑制剂,包含治疗有效量的新型DPP IV抑制剂的药物组合物,以及治疗医学病症的新方法。 本文描述的DPP IV的新型抑制剂可用于治疗神经障碍,糖尿病,炎症性疾病如关节炎,肥胖症,骨质疏松症以及可用DPP IV抑制剂治疗的其他列举的病症。
-
7.Compounds, pharmaceutical compositions, and methods for stimulating neuronal growth and elongation 失效
标题翻译: 化合物,药物组合物和刺激神经元生长和伸长的方法公开(公告)号:US06630472B1
公开(公告)日:2003-10-07
申请号:US09356240
申请日:1999-07-16
申请人: Susumu Katoh , Hiroshi Kawakami , Hiroki Tada , Maria Angelica Linton , Vincent Kalish , John Howard Tatlock , Jesus Ernesto Villafranca
发明人: Susumu Katoh , Hiroshi Kawakami , Hiroki Tada , Maria Angelica Linton , Vincent Kalish , John Howard Tatlock , Jesus Ernesto Villafranca
IPC分类号: C07D47118
CPC分类号: C07D471/08
摘要: Compounds that inhibit the peptidyl-prolyl isomerase (rotamase) enzyme activity of the FK-506 binding protein (FKBP) and compositions comprising these compounds are described. The FKBP-inhibiting compounds have a bicyclic [3.3.1], [4.3.1] or polycyclic azaamide nucleus. Pharmaceutical compositions containing such compounds help stimulate the outgrowth of neurites in nerve cells and augmenting nerve regeneration. Methods of treating nerve cells with such compositions are useful to promote repair of neuronal damage caused by disease and physical trauma.
摘要翻译: 描述了抑制FK-506结合蛋白(FKBP)的肽基 - 脯氨酰异构酶(旋转异构酶)酶活性的化合物和包含这些化合物的组合物。 FKBP抑制化合物具有双环[3.3.1],[4.3.1]或多环氮杂酰胺核。 含有这些化合物的药物组合物有助于刺激神经细胞中神经突的生长并增加神经再生。 用这种组合物治疗神经细胞的方法可用于促进由疾病和身体创伤引起的神经元损伤的修复。
-
公开(公告)号:US07235557B2
公开(公告)日:2007-06-26
申请号:US11357334
申请日:2006-02-21
申请人: Dana Victor Ferraris , Jia-He Li , Vincent Kalish , Jie Zhang
发明人: Dana Victor Ferraris , Jia-He Li , Vincent Kalish , Jie Zhang
CPC分类号: A61K31/55 , A61K31/551 , C07D471/04 , C07D487/06 , C07D495/06
摘要: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
摘要翻译: 本发明涉及化合物,药物组合物和使用所公开的化合物抑制PARP的方法。
-
9.Substituted 4,9-dihydrocyclopenta{imn}phenanthridine-5-ones derivatives thereof and their uses 失效
标题翻译: 取代的4,9-二氢环戊二烯并咪唑-5-酮衍生物及其用途公开(公告)号:US07157452B2
公开(公告)日:2007-01-02
申请号:US10500340
申请日:2002-12-24
申请人: Jia-He Li , Jie Zhang , Vincent Kalish
发明人: Jia-He Li , Jie Zhang , Vincent Kalish
IPC分类号: A61K31/54 , A61K31/497
CPC分类号: C07D221/18 , C07D221/12
摘要: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
摘要翻译: 本发明涉及化合物,药物组合物和使用所公开的化合物抑制PARP的方法。
-
10.COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP 有权
标题翻译: 化合物,方法和用于抑制PARP的药物组合物公开(公告)号:US20080058325A1
公开(公告)日:2008-03-06
申请号:US11834334
申请日:2007-08-06
申请人: Vincent Kalish , Jie Zhang , Weizheng Xu , Jia-He Li , Amy Xing , Qun Liu
发明人: Vincent Kalish , Jie Zhang , Weizheng Xu , Jia-He Li , Amy Xing , Qun Liu
IPC分类号: A61K31/5377 , A61K31/5025 , A61P19/02 , A61P25/24 , A61P25/28 , A61P31/18 , A61P35/00 , A61P35/02 , A61P37/06 , A61P9/10 , C07D237/26 , C07D413/14
CPC分类号: C07D487/06 , C07D471/06 , C07D491/06 , C07D491/08
摘要: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”) compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
摘要翻译: 本发明提供抑制含有这些化合物的聚(ADP-核糖)聚合酶(“PARP”)组合物的化合物和使用这些PARP抑制剂来治疗,预防和/或改善本文所述病症的作用的方法。
-
-
-
-
-
-
-
-
-